Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year High – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) reached a new 52-week high during trading on Thursday . The company traded as high as $18.12 and last traded at $16.96, with a volume of 2164145 shares trading hands. The stock had previously closed at $17.15.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DFTX shares. Canaccord Genuity Group boosted their price objective on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, November 7th. Jones Trading started coverage on Definium Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 target price for the company. Royal Bank Of Canada lowered their price target on Definium Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, Lifesci Capital raised shares of Definium Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $30.33.

Definium Therapeutics Stock Down 1.0%

The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -8.32 and a beta of 2.57. The stock’s 50 day moving average is $12.93 and its 200 day moving average is $11.31. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). Analysts forecast that Definium Therapeutics, Inc. will post -1.35 EPS for the current year.

Insider Activity at Definium Therapeutics

In related news, insider Daniel Karlin sold 5,600 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the transaction, the insider directly owned 425,025 shares of the company’s stock, valued at $5,589,078.75. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at $10,236,972.55. The trade was a 3.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 42,667 shares of company stock valued at $561,071 over the last 90 days. 2.26% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its holdings in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BIT Capital GmbH bought a new stake in shares of Definium Therapeutics during the 3rd quarter worth $26,000. CWM LLC grew its holdings in shares of Definium Therapeutics by 67.4% in the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after acquiring an additional 1,796 shares during the last quarter. Fifth Third Bancorp raised its position in shares of Definium Therapeutics by 5,593.2% during the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after purchasing an additional 3,300 shares during the period. Finally, Sound Income Strategies LLC purchased a new stake in shares of Definium Therapeutics during the third quarter valued at $46,000. 27.91% of the stock is currently owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.